{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T09:24:10Z","timestamp":1794216250943,"version":"4.8.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Immunology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.humimm.2026.112083","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:24:56Z","timestamp":1789676696000},"page":"112083","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Self-amplifying RNA and circular RNA vaccines: Mechanisms, delivery strategies, and prospects for long-lasting immunity"],"prefix":"10.1016","volume":"87","author":[{"given":"Nageen","family":"Sardar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4700-8018","authenticated-orcid":false,"given":"Shoaib","family":"Manzoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.humimm.2026.112083_bb0005","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.3390\/v15081760","article-title":"Vaccines' new era \u2014 RNA vaccine","volume":"15","author":"Zhou","year":"2023","journal-title":"Viruses"},{"issue":"10","key":"10.1016\/j.humimm.2026.112083_bb0010","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.3390\/vaccines11101600","article-title":"In vitro transcribed RNA-based platform vaccines: past, present, and future","volume":"11","author":"Perenkov","year":"2023","journal-title":"Vaccines"},{"issue":"4","key":"10.1016\/j.humimm.2026.112083_bb0015","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3390\/v17040566","article-title":"Self-amplifying RNA: advantages and challenges of a versatile platform for vaccine development","volume":"17","author":"Vallet","year":"2025","journal-title":"Viruses"},{"issue":"43","key":"10.1016\/j.humimm.2026.112083_bb0020","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202402936","article-title":"A novel self-amplifying mRNA with decreased cytotoxicity and enhanced protein expression by macrodomain mutations","volume":"11","author":"Gong","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.humimm.2026.112083_bb0025","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/978-1-4939-6481-9_3","article-title":"Self-replicating RNA vaccine delivery to dendritic cells","volume":"1499","author":"D\u00e9moulins","year":"2016","journal-title":"Methods Mol. Biol."},{"issue":"2","key":"10.1016\/j.humimm.2026.112083_bb0030","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ymthe.2017.11.017","article-title":"Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses","volume":"26","author":"Vogel","year":"2017","journal-title":"Mol. Ther."},{"issue":"12","key":"10.1016\/j.humimm.2026.112083_bb0035","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1089\/hum.2017.121","article-title":"Improvement of in vivo expression of genes delivered by self-amplifying RNA using vaccinia virus immune evasion proteins","volume":"28","author":"Beissert","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.humimm.2026.112083_bb0040","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.105978","article-title":"Cap-independent co-expression of dsRNA-sensing and NF-\u03baB pathway inhibitors enables controllable self-amplifying RNA expression with reduced immunotoxicity","volume":"14","author":"Lim","year":"2025","journal-title":"eLife"},{"issue":"2","key":"10.1016\/j.humimm.2026.112083_bb0045","doi-asserted-by":"crossref","DOI":"10.1093\/narmme\/ugae004","article-title":"Self-amplifying RNAs generated with modified nucleotides 5-methylcytidine and 5-methyluridine mediate strong expression and immunogenicity in vivo","volume":"1","author":"Azizi","year":"2024","journal-title":"NAR Mol. Med."},{"issue":"824","key":"10.1016\/j.humimm.2026.112083_bb0050","doi-asserted-by":"crossref","first-page":"eadz2276","DOI":"10.1126\/scitranslmed.adz2276","article-title":"Incorporation of 5-methylcytidine alleviates RIG-I-mediated innate immune responses to a self-amplifying RNA vaccine","volume":"17","author":"Komori","year":"2025","journal-title":"Science Translational Medicine"},{"issue":"4","key":"10.1016\/j.humimm.2026.112083_bb0055","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3390\/v16040503","article-title":"Trans-amplifying RNA: a journey from alphavirus research to future vaccines","volume":"16","author":"Yildiz","year":"2024","journal-title":"Viruses"},{"issue":"8","key":"10.1016\/j.humimm.2026.112083_bb0060","doi-asserted-by":"crossref","first-page":"692","DOI":"10.3390\/pathogens13080692","article-title":"Advances in engineering circular RNA vaccines","volume":"13","author":"Zhang","year":"2024","journal-title":"Pathogens"},{"issue":"3","key":"10.1016\/j.humimm.2026.112083_bb0065","doi-asserted-by":"crossref","first-page":"bbaf263","DOI":"10.1093\/bib\/bbaf263","article-title":"Artificial intelligence-driven circRNA vaccine development: multimodal collaborative optimization and a new paradigm for biomedical applications","volume":"26","author":"Zhao","year":"2025","journal-title":"Brief. Bioinform."},{"key":"10.1016\/j.humimm.2026.112083_bb0070","first-page":"102","article-title":"Optimized enzymatic ligation strategies for high-yield circular RNA vaccine production","volume":"36","author":"Yu","year":"2025","journal-title":"Molecular Ther. Nucl. Acids"},{"issue":"1","key":"10.1016\/j.humimm.2026.112083_bb0075","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1038\/s41467-018-05096-6","article-title":"Engineering circular RNA for potent and stable translation in eukaryotic cells","volume":"9","author":"Wesselhoeft","year":"2018","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.humimm.2026.112083_bb0080","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/s41551-024-01306-3","article-title":"Efficient circular RNA synthesis for potent rolling circle translation","volume":"9","author":"Du","year":"2024","journal-title":"Nat. Biomed. Eng."},{"issue":"20","key":"10.1016\/j.humimm.2026.112083_bb0085","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2302191120","article-title":"Circular RNA vaccine induces potent T cell responses","volume":"120","author":"Amaya","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.humimm.2026.112083_bb0090","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3390\/ijms26010379","article-title":"Expanding the potential of circular RNA (circRNA) vaccines: a promising therapeutic approach","volume":"26","author":"Bu","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.humimm.2026.112083_bb0095","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.cpt.2024.11.003","article-title":"Circular RNA vaccines: Pioneering the next-gen cancer immunotherapy","volume":"3","author":"Das","year":"2024","journal-title":"Cancer Pathogenesis and Therapy"},{"issue":"1","key":"10.1016\/j.humimm.2026.112083_bb0100","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1038\/s41467-021-23173-1","article-title":"Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice","volume":"12","author":"Spencer","year":"2021","journal-title":"Nat. Commun."},{"issue":"38","key":"10.1016\/j.humimm.2026.112083_bb0105","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2505718122","article-title":"Circular RNA lipid nanoparticle vaccine against SARS-CoV-2","volume":"122","author":"Swingle","year":"2025","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.humimm.2026.112083_bb0110","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41551-025-01344-5","article-title":"Small circular RNAs as vaccines for cancer immunotherapy","volume":"9","author":"Zhang","year":"2025","journal-title":"Nat. Biomed. Eng."},{"issue":"6","key":"10.1016\/j.humimm.2026.112083_bb0115","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1084\/jem.20171450","article-title":"Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses","volume":"215","author":"Pardi","year":"2018","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.humimm.2026.112083_bb0120","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.01775-23","article-title":"Circular RNA vaccines with long-term lymph node-targeting delivery stability after lyophilization induce potent and persistent immune responses","volume":"15","author":"Wan","year":"2023","journal-title":"mBio"},{"issue":"10","key":"10.1016\/j.humimm.2026.112083_bb0125","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.cell.2022.03.044","article-title":"Circular RNA vaccines against SARS-CoV-2 and emerging variants","volume":"185","author":"Qu","year":"2022","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.humimm.2026.112083_bb0130","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41541-022-00549-y","article-title":"A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability","volume":"7","author":"Voigt","year":"2022","journal-title":"NPJ Vaccines"},{"issue":"12","key":"10.1016\/j.humimm.2026.112083_bb0135","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"issue":"2","key":"10.1016\/j.humimm.2026.112083_bb0140","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10213","article-title":"Cytosolic delivery of nucleic acids: the case of ionizable lipid nanoparticles","volume":"6","author":"Schlich","year":"2021","journal-title":"Bioeng. Transl. Med."},{"issue":"6","key":"10.1016\/j.humimm.2026.112083_bb0145","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1021\/acs.molpharmaceut.2c00032","article-title":"Optimization of lipid nanoparticles for saRNA expression and cellular activation using a design-of-experiment approach","volume":"19","author":"Ly","year":"2022","journal-title":"Mol. Pharm."},{"issue":"10","key":"10.1016\/j.humimm.2026.112083_bb0150","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1080\/17425247.2022.2135502","article-title":"Microfluidic production of mRNA-loaded lipid nanoparticles for vaccine applications","volume":"19","author":"Lopes","year":"2022","journal-title":"Expert Opin. Drug Deliv."},{"issue":"2","key":"10.1016\/j.humimm.2026.112083_bb0155","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10400","article-title":"Magnetic nanoparticles enhance the cellular immune response of dendritic cell tumor vaccines by realizing the cytoplasmic delivery of tumor antigens","volume":"8","author":"Huang","year":"2022","journal-title":"Bioeng. Transl. Med."},{"issue":"7","key":"10.1016\/j.humimm.2026.112083_bb0160","doi-asserted-by":"crossref","first-page":"727","DOI":"10.3390\/vaccines12070727","article-title":"An overview of nanoparticle-based delivery platforms for mRNA vaccines for treating cancer","volume":"12","author":"Lin","year":"2024","journal-title":"Vaccines"},{"issue":"30","key":"10.1016\/j.humimm.2026.112083_bb0165","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1080\/17435889.2024.2419815","article-title":"Design and development of mRNA and self-amplifying mRNA vaccine nanoformulations","volume":"19","author":"Omidi","year":"2024","journal-title":"Nanomedicine"},{"issue":"1","key":"10.1016\/j.humimm.2026.112083_bb0170","doi-asserted-by":"crossref","first-page":"9165","DOI":"10.1038\/s41467-024-54289-9","article-title":"A self-amplifying RNA RSV prefusion-F vaccine elicits potent immunity in pre-exposed and na\u00efve non-human primates","volume":"15","author":"Vijayan","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.humimm.2026.112083_bb0175","doi-asserted-by":"crossref","first-page":"1670350","DOI":"10.3389\/fimmu.2025.1670350","article-title":"The mRNA component of LNP-mRNA vaccines triggers IFNAR-dependent immune activation which attenuates the adaptive immune response","volume":"16","author":"Bar-On","year":"2025","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.humimm.2026.112083_bb0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CJI.0b013e3181f7dbe8","article-title":"Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity","volume":"34","author":"Fotin-Mleczek","year":"2011","journal-title":"J. Immunother."},{"issue":"19","key":"10.1016\/j.humimm.2026.112083_bb0185","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.3390\/polym14194195","article-title":"Design strategies for and stability of mRNA-lipid nanoparticle COVID-19 vaccines","volume":"14","author":"Liu","year":"2022","journal-title":"Polymers"},{"issue":"1","key":"10.1016\/j.humimm.2026.112083_bb0190","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1080\/14760584.2024.2354251","article-title":"Research progress on the quality control of mRNA vaccines","volume":"23","author":"Hu","year":"2024","journal-title":"Expert Rev. Vaccines"}],"container-title":["Human Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0198885926004295?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0198885926004295?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T08:42:12Z","timestamp":1794213732000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0198885926004295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0198885926004295"],"URL":"https:\/\/doi.org\/10.1016\/j.humimm.2026.112083","relation":{},"ISSN":["0198-8859"],"issn-type":[{"value":"0198-8859","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Self-amplifying RNA and circular RNA vaccines: Mechanisms, delivery strategies, and prospects for long-lasting immunity","name":"articletitle","label":"Article Title"},{"value":"Human Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humimm.2026.112083","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112083"}}